Results 131 to 140 of about 5,315 (239)

Patterns and Trends of Glucose‐Lowering Therapy in Alzheimer's Disease and Related Dementias

open access: yes
Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7592-7596, August 2026.
Huilin Tang   +7 more
wiley   +1 more source

The Impact of Polymers in Amorphous Solid Dispersion on the Bioavailability of Sulfonylureas and Meglitinides. [PDF]

open access: yesDrug Des Devel Ther
Aulifa DL   +8 more
europepmc   +1 more source

Autoimmune Disease Risk With GLP‐1RA, DPP‐4i, and SGLT2i Treatment in Patients With Diabetes

open access: yesACR Open Rheumatology, Volume 8, Issue 7, July 2026.
Objective Dipeptidyl peptidase‐4 inhibitors (DPP‐4i), glucagon‐like peptide‐1 receptor agonists (GLP‐1RA), and sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) are widely used for type 2 diabetes, yet their comparative immunologic safety is uncertain.
Arjun Mahajan   +5 more
wiley   +1 more source

Comparative safety of sulfonylurea therapies on cardiovascular and severe hypoglycemia outcomes among adults with type 2 diabetes and moderate cardiovascular risk: a target trial emulation. [PDF]

open access: yesBMJ Open Diabetes Res Care
Sklepinski S   +15 more
europepmc   +1 more source

Long‐Term Glycemic and Metabolic Profiles Observed During Imeglimin Therapy in Japanese Patients With Type 2 Diabetes Mellitus

open access: yesEndocrinology, Diabetes &Metabolism, Volume 9, Issue 4, July 2026.
In a real‐world setting, 12‐month imeglimin therapy in Japanese patients with type 2 diabetes provided sustained glycemic improvements and enhanced endogenous insulin secretion. Importantly, these durable metabolic benefits were achieved without requiring an increase in overall glucose‐lowering treatment intensity.
Yohei Fujita   +5 more
wiley   +1 more source

Sodium‐glucose cotransporter 2 inhibitors and the risk of late onset epilepsy: A real‐world cohort study

open access: yesEpilepsia, Volume 67, Issue 7, Page 3444-3456, July 2026.
Abstract Objective Late onset epilepsy (LOE) is associated with substantial morbidity. Sodium‐glucose cotransporter 2 inhibitors (SGLT2i) may exert neuroprotective effects. This study evaluated the association between SGLT2i and risk of LOE among older adults with type 2 diabetes mellitus.
Bing‐Hua Lin   +3 more
wiley   +1 more source

Identifying high-risk combinations of metformin during COVID-19. [PDF]

open access: yesPLoS One
Dimnjaković J   +5 more
europepmc   +1 more source

Oleanolic Acid Ameliorates Hepatic Lipid Metabolism and Autophagy in Type 2 Diabetic Mice via the STAT3 Signaling Pathway

open access: yesFood Science &Nutrition, Volume 14, Issue 7, July 2026.
This study demonstrates that oleanolic acid (OA) may ameliorate type 2 diabetes mellitus (T2DM) by modulating hepatic lipid metabolism and autophagy in a manner concomitant with STAT3 phosphorylation. Specifically, OA downregulates fatty acid synthesis/uptake‐related proteins (SREBP‐1, ACC, CD36), upregulates fatty acid β‐oxidation‐related protein ...
Zirui Ji   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy